Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting

dc.contributor.authorKilpeläinen Maritta
dc.contributor.authorHirvonen Tuuli
dc.contributor.authorPerkonoja Katariina
dc.contributor.authorHirsjärvi Samuli
dc.contributor.organizationfi=keuhkosairausoppi ja kliininen allergologia|en=Pulmonary Diseases and Clinical Allergology|
dc.contributor.organizationfi=tilastotiede|en=Statistics|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.42133013740
dc.contributor.organization-code1.2.246.10.2458963.20.92467408925
dc.converis.publication-id179136256
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/179136256
dc.date.accessioned2025-08-27T23:42:52Z
dc.date.available2025-08-27T23:42:52Z
dc.description.abstract<p><em>Background and Objectives:</em> This single-center retrospective study was conducted to describe clinical characteristics and the disease course of patients with interstitial lung diseases (ILD). <br></p><p><em>Materials and Methods:</em> The study included adult patients with fibrosing ILD (IPF, non-IPF fibrosing ILD (F-ILD), and non-IPF progressive pulmonary fibrosis (PPF)) treated between 2014 and 2017. Patients were followed annually from the first visit until the end of the study period in 2019. Data were collected from the Turku University Hospital data lake and analyzed using descriptive statistics.</p><p><em>Results</em>: 591 patients formed the patient cohort: 110 had IPF, 194 F-ILD, 142 PPF, and the remaining 145 patients were uncertain, F-ILD-U, whose disease progression nature could not be confirmed by FVC measurements. There were more males in each patient group and median age of the groups was similar, although there were younger patients in the PPF, F-ILD, and F-ILD-U groups. PPF patients had more UIP pattern than F-ILD patients. Exposure-related ILDs were clearly the most found ILD diagnoses for both PPF and F-ILD, followed by unclassifiable IIP. Baseline FVC % predicted reduction in every group was moderate. Half of the patients in each group had comorbidities, and the most common were cardiovascular diseases, diabetes, sleep apnea, and chronic lower respiratory diseases; F-ILD-U patients had malignant diseases as well. IPF patients had less medications than the other groups. Glucocorticoids were the most used medication in all patient groups. More PPF and F-ILD patients remained in the follow-up than IPF and F-ILD-U patients. Similarly, mortality of F-ILD-U was the highest, followed by IPF. Evolvement of lung function, oxygen use, and number of acute hospitalizations were similar for IPF and PPF patients whereas the corresponding results were always better for F-ILD patients.</p><p><i>Conclusions:</i> The disease course of IPF and PPF was similar, and PPF patient amount exceeded the amount of IPF patients.</p>
dc.identifier.eissn1648-9144
dc.identifier.jour-issn1010-660X
dc.identifier.olddbid204474
dc.identifier.oldhandle10024/187501
dc.identifier.urihttps://www.utupub.fi/handle/11111/52740
dc.identifier.urlhttps://doi.org/10.3390/medicina59020281
dc.identifier.urnURN:NBN:fi-fe2023040635273
dc.language.isoen
dc.okm.affiliatedauthorKilpeläinen, Maritta
dc.okm.affiliatedauthorPerkonoja, Katariina
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherMDPI
dc.publisher.countrySwitzerlanden_GB
dc.publisher.countrySveitsifi_FI
dc.publisher.country-codeCH
dc.relation.articlenumber281
dc.relation.doi10.3390/medicina59020281
dc.relation.ispartofjournalMedicina: Lithuania
dc.relation.issue2
dc.relation.volume59
dc.source.identifierhttps://www.utupub.fi/handle/10024/187501
dc.titleClinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
medicina-59-00281-v3.pdf
Size:
2.3 MB
Format:
Adobe Portable Document Format